The Yokohama Rubber Co., Ltd.

Seikagaku Corporation

Seikagaku Kogyo Kabushiki Kaisha (seikagaku Corporation)

The Board of the Rubber Research Institute of Malaysia

Seiichiro Ogawa

Yoshiyuki Suzuki

Morihisa Machida

Eiji Nanba

Junichiro Matsuda

Kousaku Ohno

Kunio Kageyama

Hidetoshi Tsunoda

Jinichi Inokuchi

Hiroshi Kimura

Yoshitaka Udagawa

Akihiro Isaka

Jin-ichi Inokuchi

Chikara Uchida

Methods for stabilizing &#x3b2;-galactosidase, stabilizing &#x3b2;-glucocerebrosidase, treating a glycolipid metabolic disorder caused by mutation of &#x3b2;-galactosidase gene, treating a glycolipid metabolic disorder caused by mutation of &#x3b2;-glucocerebrosidase gene, regenerating the activity of &#x3b2;-galactosidase, regenerating the activity of &#x3b2;-glucosidase, treating GM1 gangliosidosis, Morquio-B or Krabbe's disease, and treating Gaucher's disease, include administering a carba-sugar amine derivative represented by the following formula (1) or (2): 

Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient

A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a &#x3b2;-galactosidase inhibitor or a glycolipid metabolic disorder treating agent.  Wherein each of Rand Rindependently represents H, an alkyl group, an acyl group, an aryl group or an aralkyl group, with the proviso that both are not H at the same time, and each of R, R, Rand Rindependently represents a hydroxyl group or hydroxyl group having a substituent. Also, Rrepresents an alkyl group, and each of R, R, Rand Rindependently represents a hydroxyl group or a hydroxyl group having a substituent.

The present invention provides a compound which is a glycolipid analog having a novel structure represented by the formula (1): ##STR1## wherein Z represents an imino group, an oxygen atom or a sulfur atom; m is an integer of from 3 to 12; and n is an integer of from 4 to 22; and shows a potent activity of inhibiting glycosidase and has potential physiological activities, for example, antiviral activity. The invention also provides a glycosidase inhibitor which comprises said glycolipid analog as an active ingredient.

Glycolipid analogs

The present invention provides aminocyclopentane derivatives which are saccharide analogs having extremely high .alpha.-glucosidase inhibitory effects and novel structures and expected to be usable or applicable to drugs or agricultural chemicals. An aminocyclopentane derivative represented by the formula (1), wherein R.sub.1 represents H while R.sub.2 represents CH.sub.2 OH, or R.sub.1 represents CH.sub.2 OH while R.sub.2 represents H and R.sub.3 represents a substituted or unsubstituted aryl group or an alkyl, alkenyl, alkynyl or hydroxyalkyl group having 1 to 10 carbon atoms, intermediates for the synthesis of the same, a process for producing the intermediates and a process for producing the aminocyclopentane derivative. ##STR1##

Aminocyclopentane derivative

Inositol compounds grouped into an aminocyclitol family are disclosed which have stereospecific structure and optical activity and find application to the manufacture of medicinal products and agricultural chemicals. The compound is produced with use of optically active L-quebrachitol as a starting material and by way of specific steps of reaction.

Optically active aminocyclitols

Purified L-quebrachitol is recovered in increased quantities from rubber latex by dissolving concentrated solutions or pulverized solids of the serums in methyl alcohol under specified extraction conditions.

Growing community of inventors

Tokyo, Japan

Seiichiro Ogawa